Collaborations & Alliances

Sanofi Extends MyoKardia Collaboration

MyoKardia earns $45 million milestone with advancement of two compounds

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi has decided to continue the global cardiomyopathy research collaboration with MyoKardia formed in August 2014. MyoKardia is now eligible for a $45 million milestone payment payable by January 31, 2017.   The agreement focuses on heritable cardiomyopathies and includes three MyoKardia programs. Two of these programs are focused on hypertrophic cardiomyopathy (HCM) and one targets dilated cardiomyopathy (DCM).   MyoKardia’s lead product candidate MYK-461 in the initial indication of sym...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters